DBV TECHNOLOGIES |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.29 EUR | +1.57% |
|
+6.97% | -30.23% |
| 08:53am | DBV Technologies: towards a change in ADS ratio | CF |
| May. 17 | European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 6.37M 6.93M | Sales 2025 * | 4.98M 5.41M | Capitalization | 122M 133M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M -136M | Net income 2025 * | -118M -128M | EV / Sales 2024 * | -6.72 x |
| Net cash position 2024 * | 165M 179M | Net cash position 2025 * | 226M 245M | EV / Sales 2025 * | -20.8 x |
| P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-3.32
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | +1.57% | ||
| 1 week | +6.97% | ||
| Current month | +3.70% | ||
| 1 month | +6.61% | ||
| 3 months | -3.95% | ||
| 6 months | -21.34% | ||
| Current year | -30.23% |
1 week
1.20
1.48
1 month
1.181.48
Current year
1.101.90
1 year
1.103.92
3 years
1.1010.90
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1.29 | +1.57% | 16 875 |
| 24-05-17 | 1.27 | -2.61% | 125,099 |
| 24-05-16 | 1.304 | +5.16% | 314,082 |
| 24-05-15 | 1.24 | +2.14% | 103,662 |
| 24-05-14 | 1.214 | +0.66% | 59,618 |
Real-time Euronext Paris, May 20, 2024 at 03:34 am EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.27
EUR
Average target price
4.733
EUR
Spread / Average Target
+272.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.23% | 133M | |
| +10.49% | 8.96B | |
| -10.76% | 5.19B | |
| +51.58% | 4.77B | |
| +12.50% | 4.26B | |
| -20.70% | 2.37B | |
| +13.33% | 2.3B | |
| -29.65% | 2.21B | |
| +19.51% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- DBV Stock
